Search tips
Search criteria 


Logo of jcmPermissionsJournals.ASM.orgJournalJCM ArticleJournal InfoAuthorsReviewers
J Clin Microbiol. 1994 March; 32(3): 618–622.
PMCID: PMC263096

Ability of canine Lyme disease vaccine to protect hamsters against infection with several isolates of Borrelia burgdorferi.


We used flow cytometry to determine levels of borreliacidal antibodies in hamsters after vaccination with a commercially available canine Lyme disease vaccine. In addition, we evaluated the ability of vaccinated hamsters to resist infection with several isolates of Borrelia burgdorferi. Borreliacidal antibodies could be detected 1 week after a primary vaccination, peaked at weeks 3 to 5, and then rapidly declined. One week after a booster vaccination, borreliacidal activity was detected at a dilution of 1:10,240, and it decreased fourfold by week 10 after the booster vaccination. Vaccinated hamsters were protected against infection with < or = 10(6) B. burgdorferi 297 organisms during the peak borreliacidal response (5 weeks after primary vaccination or 2 weeks after booster vaccination). However, hamsters were not fully protected from development of Lyme arthritis when the titer of borreliacidal antibodies was < 1:5,120. In addition, no significant borreliacidal activity was induced against B. burgdorferi C-1-11, LV4, or BV1, which belong to three other seroprotective groups. These studies demonstrate that vaccination with the canine Lyme disease vaccine induces protective antibodies against B. burgdorferi 297. However, significant levels of borreliacidal antibodies are not produced until 5 weeks after vaccination, and protection is short-lived. In addition, no borreliacidal activity was induced against other isolates of B. burgdorferi. Because of this, the incorporation of multiple isolates or protein subunits may be necessary to increase the effectiveness of future vaccines.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Barbour AG. Isolation and cultivation of Lyme disease spirochetes. Yale J Biol Med. 1984 Jul-Aug;57(4):521–525. [PMC free article] [PubMed]
  • Barbour AG, Tessier SL, Todd WJ. Lyme disease spirochetes and ixodid tick spirochetes share a common surface antigenic determinant defined by a monoclonal antibody. Infect Immun. 1983 Aug;41(2):795–804. [PMC free article] [PubMed]
  • Boerlin P, Peter O, Bretz AG, Postic D, Baranton G, Piffaretti JC. Population genetic analysis of Borrelia burgdorferi isolates by multilocus enzyme electrophoresis. Infect Immun. 1992 Apr;60(4):1677–1683. [PMC free article] [PubMed]
  • Callister SM, Case KL, Agger WA, Schell RF, Johnson RC, Ellingson JL. Effects of bovine serum albumin on the ability of Barbour-Stoenner-Kelly medium to detect Borrelia burgdorferi. J Clin Microbiol. 1990 Feb;28(2):363–365. [PMC free article] [PubMed]
  • Callister SM, Schell RF, Case KL, Lovrich SD, Day SP. Characterization of the borreliacidal antibody response to Borrelia burgdorferi in humans: a serodiagnostic test. J Infect Dis. 1993 Jan;167(1):158–164. [PubMed]
  • Chu HJ, Chavez LG, Jr, Blumer BM, Sebring RW, Wasmoen TL, Acree WM. Immunogenicity and efficacy study of a commercial Borrelia burgdorferi bacterin. J Am Vet Med Assoc. 1992 Aug 1;201(3):403–411. [PubMed]
  • Fikrig E, Barthold SW, Kantor FS, Flavell RA. Long-term protection of mice from Lyme disease by vaccination with OspA. Infect Immun. 1992 Mar;60(3):773–777. [PMC free article] [PubMed]
  • Fikrig E, Barthold SW, Marcantonio N, Deponte K, Kantor FS, Flavell RA. Roles of OspA, OspB, and flagellin in protective immunity to Lyme borreliosis in laboratory mice. Infect Immun. 1992 Feb;60(2):657–661. [PMC free article] [PubMed]
  • Fikrig E, Barthold SW, Persing DH, Sun X, Kantor FS, Flavell RA. Borrelia burgdorferi strain 25015: characterization of outer surface protein A and vaccination against infection. J Immunol. 1992 Apr 1;148(7):2256–2260. [PubMed]
  • Johnson RC, Kodner C, Russell M. Active immunization of hamsters against experimental infection with Borrelia burgdorferi. Infect Immun. 1986 Dec;54(3):897–898. [PMC free article] [PubMed]
  • Johnson RC, Kodner C, Russell M, Duray PH. Experimental infection of the hamster with Borrelia burgdorferi. Ann N Y Acad Sci. 1988;539:258–263. [PubMed]
  • Kazmierczak JJ, Sorhage FE. Current understanding of Borrelia burgdorferi infection, with emphasis on its prevention in dogs. J Am Vet Med Assoc. 1993 Dec 1;203(11):1524–1528. [PubMed]
  • Lim LC, Liu YF, Schell K, Lovrich SD, Callister SM, Schell RF. Detection of borreliacidal antibody by using acridine orange and flow cytometry. Clin Diagn Lab Immunol. 1994 Jan;1(1):44–50. [PMC free article] [PubMed]
  • Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. N Engl J Med. 1990 Nov 22;323(21):1438–1444. [PubMed]
  • Lovrich SD, Callister SM, Lim LC, Schell RF. Seroprotective groups among isolates of Borrelia burgdorferi. Infect Immun. 1993 Oct;61(10):4367–4374. [PMC free article] [PubMed]
  • Lovrich SD, Callister SM, Schmitz JL, Alder JD, Schell RF. Borreliacidal activity of sera from hamsters infected with the Lyme disease spirochete. Infect Immun. 1991 Aug;59(8):2522–2528. [PMC free article] [PubMed]
  • Magnarelli LA, Anderson JF, Kaufmann AF, Lieberman LL, Whitney GD. Borreliosis in dogs from southern Connecticut. J Am Vet Med Assoc. 1985 May 1;186(9):955–959. [PubMed]
  • Magnarelli LA, Anderson JF, Schreier AB, Ficke CM. Clinical and serologic studies of canine borreliosis. J Am Vet Med Assoc. 1987 Nov 1;191(9):1089–1094. [PubMed]
  • Marconi RT, Garon CF. Phylogenetic analysis of the genus Borrelia: a comparison of North American and European isolates of Borrelia burgdorferi. J Bacteriol. 1992 Jan;174(1):241–244. [PMC free article] [PubMed]
  • McAlister HF, Klementowicz PT, Andrews C, Fisher JD, Feld M, Furman S. Lyme carditis: an important cause of reversible heart block. Ann Intern Med. 1989 Mar 1;110(5):339–345. [PubMed]
  • Schmitz JL, Schell RF, Callister SM, Lovrich SD, Day SP, Coe JE. Immunoglobulin G2 confers protection against Borrelia burgdorferi infection in LSH hamsters. Infect Immun. 1992 Jul;60(7):2677–2682. [PMC free article] [PubMed]
  • Schmitz JL, Schell RF, Hejka AG, England DM. Passive immunization prevents induction of Lyme arthritis in LSH hamsters. Infect Immun. 1990 Jan;58(1):144–148. [PMC free article] [PubMed]
  • Schmitz JL, Schell RF, Lovrich SD, Callister SM, Coe JE. Characterization of the protective antibody response to Borrelia burgdorferi in experimentally infected LSH hamsters. Infect Immun. 1991 Jun;59(6):1916–1921. [PMC free article] [PubMed]
  • Simon MM, Schaible UE, Kramer MD, Eckerskorn C, Museteanu C, Müller-Hermelink HK, Wallich R. Recombinant outer surface protein a from Borrelia burgdorferi induces antibodies protective against spirochetal infection in mice. J Infect Dis. 1991 Jul;164(1):123–132. [PubMed]
  • Steere AC, Bartenhagen NH, Craft JE, Hutchinson GJ, Newman JH, Rahn DW, Sigal LH, Spieler PN, Stenn KS, Malawista SE. The early clinical manifestations of Lyme disease. Ann Intern Med. 1983 Jul;99(1):76–82. [PubMed]
  • Steere AC, Grodzicki RL, Kornblatt AN, Craft JE, Barbour AG, Burgdorfer W, Schmid GP, Johnson E, Malawista SE. The spirochetal etiology of Lyme disease. N Engl J Med. 1983 Mar 31;308(13):733–740. [PubMed]
  • Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med. 1987 Nov;107(5):725–731. [PubMed]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)